Growth Metrics

Acumen Pharmaceuticals (ABOS) Non-Current Deffered Revenue (2022 - 2023)

Acumen Pharmaceuticals recorded quarterly Non-Current Deffered Revenue of $183000.0 in Q2 2023, down 45.7% quarter-over-quarter from $337000.0 in Q3 2022, and down 23.11% year-over-year from $238000.0 in Q2 2022.

Acumen Pharmaceuticals' Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $183000.0 for Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 225.10 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Acumen Pharmaceuticals 164.37 Mn 35.97 Mn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2023 183,000.00
Sep 30, 2022 337,000.00
Jun 30, 2022 238,000.00